Basic and clinical studies on loracarbef in the urological field

Toyohiko Watanabe, T. Takenaka, T. Hayasi, K. Hata, N. Ono, H. Kumon, Y. Ohmori

Research output: Contribution to journalArticle

Abstract

We studied the antibacterial activity and efficacy of loracarbef (LCBF), a new carbacephem antibiotic, in the urological field. 1. Antibacterial activity: The MICs of LCBF were measured against 205 clinical isolates of 14 species from urinary tract infections and compared with those of cefixime (CFIX), cefteram pivoxil (CFTM-PI) and cefaclor (CCL). In general, the antibacterial activities of LCBF were almost equal to those of CCL. 2. Clinical efficacy in complicated urinary tract infection was evaluated according to the criteria of the Japanese UTI Committee. The clinical response in 8 evaluable patients was considered excellent in 4, moderate in 3 and poor in 1. Seven (87.5%) of 8 strains isolated were eradicated. 3. The concentration of LCBF in expressed prostatic secretion (EPS) was studied after oral administration of the drug at a dose of 200 mg. Four hours after the administration of LCBF, the concentration of EPS reached 0.48 ± 0.16 μg/ml (n = 3), and the ratio between serum and EPS was 0.28 ± 0.12. 4. Side effects: Diarrhea and abdominal pain were observed in 1 patient. Both symptoms were mild and transient. Based on the above findings, it is considered that LCBF is useful in the treatment of urinary tract infection.

Original languageEnglish
Pages (from-to)310-317
Number of pages8
JournalChemotherapy
Volume41
Issue numberSUPPL. 3
Publication statusPublished - 1993

Fingerprint

loracarbef
Urinary Tract Infections
Cefaclor
Cefixime
Abdominal Pain
Oral Administration
Clinical Studies
Diarrhea
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Pharmacology

Cite this

Watanabe, T., Takenaka, T., Hayasi, T., Hata, K., Ono, N., Kumon, H., & Ohmori, Y. (1993). Basic and clinical studies on loracarbef in the urological field. Chemotherapy, 41(SUPPL. 3), 310-317.

Basic and clinical studies on loracarbef in the urological field. / Watanabe, Toyohiko; Takenaka, T.; Hayasi, T.; Hata, K.; Ono, N.; Kumon, H.; Ohmori, Y.

In: Chemotherapy, Vol. 41, No. SUPPL. 3, 1993, p. 310-317.

Research output: Contribution to journalArticle

Watanabe, T, Takenaka, T, Hayasi, T, Hata, K, Ono, N, Kumon, H & Ohmori, Y 1993, 'Basic and clinical studies on loracarbef in the urological field', Chemotherapy, vol. 41, no. SUPPL. 3, pp. 310-317.
Watanabe T, Takenaka T, Hayasi T, Hata K, Ono N, Kumon H et al. Basic and clinical studies on loracarbef in the urological field. Chemotherapy. 1993;41(SUPPL. 3):310-317.
Watanabe, Toyohiko ; Takenaka, T. ; Hayasi, T. ; Hata, K. ; Ono, N. ; Kumon, H. ; Ohmori, Y. / Basic and clinical studies on loracarbef in the urological field. In: Chemotherapy. 1993 ; Vol. 41, No. SUPPL. 3. pp. 310-317.
@article{13292d94ad0947cf92868d0119c2f0fa,
title = "Basic and clinical studies on loracarbef in the urological field",
abstract = "We studied the antibacterial activity and efficacy of loracarbef (LCBF), a new carbacephem antibiotic, in the urological field. 1. Antibacterial activity: The MICs of LCBF were measured against 205 clinical isolates of 14 species from urinary tract infections and compared with those of cefixime (CFIX), cefteram pivoxil (CFTM-PI) and cefaclor (CCL). In general, the antibacterial activities of LCBF were almost equal to those of CCL. 2. Clinical efficacy in complicated urinary tract infection was evaluated according to the criteria of the Japanese UTI Committee. The clinical response in 8 evaluable patients was considered excellent in 4, moderate in 3 and poor in 1. Seven (87.5{\%}) of 8 strains isolated were eradicated. 3. The concentration of LCBF in expressed prostatic secretion (EPS) was studied after oral administration of the drug at a dose of 200 mg. Four hours after the administration of LCBF, the concentration of EPS reached 0.48 ± 0.16 μg/ml (n = 3), and the ratio between serum and EPS was 0.28 ± 0.12. 4. Side effects: Diarrhea and abdominal pain were observed in 1 patient. Both symptoms were mild and transient. Based on the above findings, it is considered that LCBF is useful in the treatment of urinary tract infection.",
author = "Toyohiko Watanabe and T. Takenaka and T. Hayasi and K. Hata and N. Ono and H. Kumon and Y. Ohmori",
year = "1993",
language = "English",
volume = "41",
pages = "310--317",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Basic and clinical studies on loracarbef in the urological field

AU - Watanabe, Toyohiko

AU - Takenaka, T.

AU - Hayasi, T.

AU - Hata, K.

AU - Ono, N.

AU - Kumon, H.

AU - Ohmori, Y.

PY - 1993

Y1 - 1993

N2 - We studied the antibacterial activity and efficacy of loracarbef (LCBF), a new carbacephem antibiotic, in the urological field. 1. Antibacterial activity: The MICs of LCBF were measured against 205 clinical isolates of 14 species from urinary tract infections and compared with those of cefixime (CFIX), cefteram pivoxil (CFTM-PI) and cefaclor (CCL). In general, the antibacterial activities of LCBF were almost equal to those of CCL. 2. Clinical efficacy in complicated urinary tract infection was evaluated according to the criteria of the Japanese UTI Committee. The clinical response in 8 evaluable patients was considered excellent in 4, moderate in 3 and poor in 1. Seven (87.5%) of 8 strains isolated were eradicated. 3. The concentration of LCBF in expressed prostatic secretion (EPS) was studied after oral administration of the drug at a dose of 200 mg. Four hours after the administration of LCBF, the concentration of EPS reached 0.48 ± 0.16 μg/ml (n = 3), and the ratio between serum and EPS was 0.28 ± 0.12. 4. Side effects: Diarrhea and abdominal pain were observed in 1 patient. Both symptoms were mild and transient. Based on the above findings, it is considered that LCBF is useful in the treatment of urinary tract infection.

AB - We studied the antibacterial activity and efficacy of loracarbef (LCBF), a new carbacephem antibiotic, in the urological field. 1. Antibacterial activity: The MICs of LCBF were measured against 205 clinical isolates of 14 species from urinary tract infections and compared with those of cefixime (CFIX), cefteram pivoxil (CFTM-PI) and cefaclor (CCL). In general, the antibacterial activities of LCBF were almost equal to those of CCL. 2. Clinical efficacy in complicated urinary tract infection was evaluated according to the criteria of the Japanese UTI Committee. The clinical response in 8 evaluable patients was considered excellent in 4, moderate in 3 and poor in 1. Seven (87.5%) of 8 strains isolated were eradicated. 3. The concentration of LCBF in expressed prostatic secretion (EPS) was studied after oral administration of the drug at a dose of 200 mg. Four hours after the administration of LCBF, the concentration of EPS reached 0.48 ± 0.16 μg/ml (n = 3), and the ratio between serum and EPS was 0.28 ± 0.12. 4. Side effects: Diarrhea and abdominal pain were observed in 1 patient. Both symptoms were mild and transient. Based on the above findings, it is considered that LCBF is useful in the treatment of urinary tract infection.

UR - http://www.scopus.com/inward/record.url?scp=0027527884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027527884&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027527884

VL - 41

SP - 310

EP - 317

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - SUPPL. 3

ER -